Post-effective amendment to a registration statement that is not immediately effective upon filing

SCHEDULE OF REVENUE RECOGNITION (Details)

v3.25.2
SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Product Information [Line Items]        
Total net revenue $ 1,853,597 $ 2,406,391 $ 9,362,022 $ 2,532,499
Health Care, Patient Service [Member]        
Product Information [Line Items]        
Total net revenue 1,570,382 [1] 2,149,049 [1] 8,175,670 [2] 2,199,558 [2]
Histology Service Fees [Member]        
Product Information [Line Items]        
Total net revenue 263,754 237,972 1,103,751 272,660
Medical Director Fees [Member]        
Product Information [Line Items]        
Total net revenue 16,588 16,058 66,576 19,324
Department of Defense Observational Studies [Member]        
Product Information [Line Items]        
Total net revenue 2,885 8,654 19,442
Other Revenues [Member]        
Product Information [Line Items]        
Total net revenue $ 2,873 $ 427 $ 7,371 $ 21,515
[1] Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $169,000 and $45,000 for the three months ended March 31, 2025 and 2024, respectively.
[2] Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $516,000 and $35,000 for the years ended December 31, 2024 and 2023.